KRAS and BRAF mutations in anal carcinoma
- 22 September 2014
- Vol. 123 (1), 53-59
- https://doi.org/10.1111/apm.12306
Abstract
The EGF receptor (EGFR) is expressed in most cases of anal carcinomas. Anecdotal benefit from EGFR-targeted therapy has been reported in anal cancer and a negative correlation with Kirsten Ras (KRAS) mutation status has been proposed. The purpose of this retrospective study was to investigate the frequency and the prognostic value of KRAS and BRAF mutations in a large cohort of patients with anal cancer. One hundred and ninety-three patients with T1-4N0-3M0-1 anal carcinoma were included in the study. Patients were treated with curative (92%) or palliative intent (8%) between January 2000 and January 2010. KRAS mutations were detected using Therascreen(®)KRAS real-time PCR assay (Qiagen) and V600E or V600D/K BRAF mutations were uncovered using Pyrosequencing. The frequency of KRAS and BRAF mutations was low; KRAS mutations were detected in 1.6% and BRAF mutations in 4.7% of the biopsies. No impact of KRAS or BRAF status on survival was found. In conclusion, both KRAS and BRAF mutations are rare in anal cancer. The low frequency of KRAS mutations support protocols exploring EGFR-targeted therapy in patients with metastatic anal cancer, while treatment with BRAF inhibitors might be relevant for only a very few patients.Keywords
Funding Information
- CIRRO - The Lundbeck Foundation Center for Interventional Research in Radiation Oncology and the Danish Council for Strategic Research
- Fabrikant Einar Willumsens Mindelegat
- Fabrikant Frands K�hler Nielsens og Hustrus Mindelegat
- Torben og Alice Frimodts Fond
This publication has 38 references indexed in Scilit:
- Prognostic factors for recurrence and survival in anal cancerCancer, 2012
- Management of Local Disease RelapseColorectal Disease, 2011
- Prognostic factors derived from a prospective database dictate clinical biology of anal cancerCancer, 2010
- Outcomes and Prognostic Factors for Squamous-Cell Carcinoma of the Anal CanalDiseases of the Colon & Rectum, 2009
- Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282Investigational New Drugs, 2006
- Combined Multimodal Approach to the Treatment of Metastatic Anal Carcinoma: Report of a Case and Review of the LiteratureOncology Research and Treatment, 2006
- Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomasCancer, 2001
- Conservative treatment by irradiation of epidermoid cancers of the anal canal: Prognostic factors of tumoral control and complicationsInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycinThe Lancet, 1996
- Treatment of Relapsing Anal CarcinomaActa Oncologica, 1993